Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types

INTRODUCTION: NKR-2 are autologous T cells genetically modified to express a chimeric antigen receptor (CAR) comprising a fusion of the natural killer group 2D (NKG2D) receptor with the CD3ζ signalling domain, which associates with the adaptor molecule DNAX-activating protein of 10 kDa (DAP10) to pr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMJ Open
Main Authors: Lonez, Caroline, Verma, Bikash, Hendlisz, Alain, Aftimos, Philippe, Awada, Ahmad, Van Den Neste, Eric, Catala, Gaetan, Machiels, Jean-Pascal H, Piette, Fanny, Brayer, Jason B, Sallman, David A, Kerre, Tessa, Odunsi, Kunle, Davila, Marco L, Gilham, David E, Lehmann, Frédéric F
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2017
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5695348/
https://ncbi.nlm.nih.gov/pubmed/29133316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2017-017075
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados